As CMS restructures reimbursement for skin substitutes and other cellular and tissue-based products (CTPs), uncertainty continues to ripple across the wound care landscape. In this interview, Rob Odell, Founder and CEO of Bobber Biotech,...
As CMS restructures reimbursement for skin substitutes and other cellular and tissue-based products (CTPs), uncertainty continues to ripple across the wound care landscape. In this interview, Rob Odell, Founder and CEO of Bobber Biotech,...
As CMS restructures...